A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
intellectual property
Posted inHealth and Social Policy
Making the Next Coronavirus Vaccine Truly Public
The vaccine developed at the Walter Reed Army Institute should not be privatized for maximum profit.
Posted inMoney, Politics, and Power
Spotify’s Risk Doesn’t End With Joe Rogan
Artists angered about misinformation might also look at their tiny paychecks from the streaming giant.
Posted inMoney, Politics, and Power
Rollups: The Emerging Magic Mushroom Monopoly
Compass Pathways has been aggressively using patent claims to corner the market on psychedelic-assisted treatments.
Posted inTAP
Bipartisanship Lives—Thanks to China
Today on TAP: Schumer moves to add a major technology bill to the must-pass defense authorization.
Posted inCoronavirus
How to Vaccinate the World
There’s a lot more the Biden administration can do to stop the pandemic—like no more kowtowing to pharma.
Posted inTAP
Vaccine Update: Pfizer Sticks It to Uncle Sam
Today on TAP: The drug industry and global vaccine needs
Posted inHealth and Social Policy
House, Senate Spar Over Reducing Drug Prices
There’s overwhelming support among Democrats for finally allowing Medicare to negotiate with drug companies. But the details matter.
Posted inCoronavirus
Why Pfizer’s Friends Want Biden to Intervene in Brazil
The pharma giant is trying to squash a bill that would expand vaccine access.
Posted inTAP
Biden’s Worldwide Vaccine Policy—Big Pharma Keeps Winning
Today on TAP: The disgraceful gap between the administration’s words and deeds